2011
DOI: 10.1007/s12185-011-0986-5
|View full text |Cite
|
Sign up to set email alerts
|

TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients

Abstract: T-cell prolymphocytic leukemia (T-PLL) is a rare type of peripheral T-cell leukemia. In this study, we examined the clinical and biological characteristics of 11 Japanese patients with T-PLL. Median age was 74 years, with male predominance. Median lymphocyte frequency was 85.3% in blood. Physical characteristics were splenomegaly (36.4%), tiny lymph adenopathy (63.6%), skin lesion (9.1%) and pleural effusion (27.3%). Median survival was 30.1 months, despite treatment with various chemotherapeutic modalities. A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
9
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(12 citation statements)
references
References 34 publications
3
9
0
Order By: Relevance
“…Although the male-to-female ratios and medians in this study were consistent with those of previous studies, 1,17,18 of T-PLL patients in the present study were 60.9 months and 57.5%, respectively. These results are similar to those previously reported in Japanese patients.…”
Section: Discussionsupporting
confidence: 92%
See 2 more Smart Citations
“…Although the male-to-female ratios and medians in this study were consistent with those of previous studies, 1,17,18 of T-PLL patients in the present study were 60.9 months and 57.5%, respectively. These results are similar to those previously reported in Japanese patients.…”
Section: Discussionsupporting
confidence: 92%
“…Although the male‐to‐female ratios and medians in this study were consistent with those of previous studies, the frequencies of clinical manifestations including CNS involvement, hepatomegaly, splenomegaly, and pleural effusion were much lower than previously reported in patients of a Western country by Matutes et al . Moreover, while the median survival of T‐PLL patients in the United Kingdom and the United States in 2002 was reported to be less than 12 months despite the administration of alemtuzumab (Campath‐1H) for relapsed/refractory cases, the median survival and 5‐year OS of T‐PLL patients in the present study were 60.9 months and 57.5%, respectively.…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…It is known that TCL1 is negative in normal T cells, and TCL1 rearrangement is absent in various other types of T cell neoplasms 8. TCL1 protein expression was reported to be absent in T cell neoplasms other than T-PLL in a small series 28. We performed TCL1 IHC on seven PTCL cases with BM and PB involvement; all were negative (data not shown).…”
Section: Discussionmentioning
confidence: 87%
“…It is noteworthy that subset expression (in <30% tumour cells) was observed in 8/51 (16%) cases, including 2 cases where FISH was performed showing TCL1 rearrangement in most of the tumour cells. Different levels of TCL1 expression have been observed in T-PLL by real-time quantitative PCR28 or by IHC 6. A high level of TCL1 oncoprotein expression has been associated with a higher WBC count at presentation, faster tumour cell doubling and enhanced in vitro growth response to T cell receptor engagement 6.…”
Section: Discussionmentioning
confidence: 99%